Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC

September 15th 2025

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Expert-Backed Roadmap Guides Outpatient Bispecific Antibody Use in Myeloma

September 14th 2025

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

Five Under 5: Top Oncology Videos for the Week of 9/7

September 14th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 9/7

September 13th 2025

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Trastuzumab Pamirtecan Hits Phase 3 PFS End Point in HER2+ Metastatic Breast Cancer

September 12th 2025

Trastuzumab pamirtecan improved progression-free survival in HER2-positive advanced breast cancer after prior trastuzumab and taxane-based chemotherapy.

Bexobrutideg Shows Early Promise in BTK- and BCL2-Exposed, Relapsed/Refractory CLL

September 12th 2025

The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.

Orelabrutinib Receives Approval in Singapore for Marginal Zone Lymphoma

September 11th 2025

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

Relacorilant NDA Is Under FDA Review for Platinum-Resistant Ovarian Cancer

September 10th 2025

The FDA accepted a NDA for relacorilant in platinum-resistant ovarian cancer based on data from ROSELLA and other phase 2 trials.

Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC

September 10th 2025

Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.

Cemiplimab Plus Chemotherapy Provides Long-Term Survival Benefit in Advanced NSCLC

September 10th 2025

Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.

SKYSCRAPER-05 Data Confirm Surgical Feasibility After Perioperative Tiragolumab Combo in NSCLC

September 9th 2025

The SKYSCRAPER-05 trial shed light on the use of perioperative tiragolumab plus atezolizumab with or without chemotherapy in NSCLC.

Taletrectinib Demonstrates Durable Responses in TKI-Naive and -Pretreated ROS1+ NSCLC

September 8th 2025

Taletrectinib delivered high response rates and durable benefit with manageable safety in ROS1-positive non–small cell lung cancer.

Ifinatamab Deruxtecan Elicits Responses in Previously Treated Extensive-Stage Small Cell Lung Cancer

September 7th 2025

Ifinatamab deruxtecan was efficacious and had a manageable safety profile in patients with previously treated extensive-stage small cell lung cancer.

Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC

September 7th 2025

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

Frontline Osimertinib Plus Chemo Significantly Improves OS in EGFR-Mutated Advanced NSCLC

September 7th 2025

Updated FLAURA2 OS data confirm osimertinib plus chemotherapy as a first-line SOC treatment in EGFR-mutated advanced NSCLC.

Five Under 5: Top Oncology Videos for the Week of 8/31

September 7th 2025

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

CheckMate 77T QOL Data Further Support Perioperative Nivolumab in Resectable NSCLC

September 7th 2025

Perioperative nivolumab maintained HRQOL and decreased the risk of deterioration vs placebo in patients with stage III N2 NSCLC.

Continuing Osimertinib Plus Chemo After Progression Improves PFS in EGFR-Mutated NSCLC

September 6th 2025

COMPEL data support osimertinib plus chemotherapy in EGFR-mutated NSCLC after non-CNS progression on frontline osimertinib.

Frontline Iza-Bren Plus Osimertinib Elicits 100% ORR in EGFR-Mutant NSCLC

September 6th 2025

First-line iza-bren plus osimertinib demonstrated a manageable safety profile with preliminary antitumor activity in EGFR-mutant NSCLC.

Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL

September 6th 2025

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.